Ronald Petersen

, MD, PhD

Professor of Neurology; Cora Kanow Professor of Alzheimer’s Disease Research; Director, Mayo Alzheimer’s Disease Research Center, Mayo Clinic College of Medicine

Dr. Ronald C. Petersen received a PhD in Experimental Psychology from the University of Minnesota and graduated from Mayo Medical School in Rochester, Minn., in 1980.  He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Mass. Dr. Petersen joined the staff of the Mayo Clinic in 1986 and became a Professor of Neurology in 1996. He was named the Cora Kanow Professor of Alzheimer’s Disease Research in 2000 and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1,000 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease.  

Dr. Petersen is one of the recipients of the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. He received the Khachaturian Award in 2012 and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer’s Association.  In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Disease Plan, and in 2014, he was appointed to the World Dementia Council by the UK government.  In 2021, he was given the Lifetime Achievement Award for Alzheimer’s Disease Therapeutic Research.

Read more

This Speaker's Sessions

Wednesday Oct. 18
1:30–2:15 PM
Watch Replay
Now Live!

Meeting Patient Demand for Alzheimer's Treatment

The treatment of Alzheimer’s continues to improve. As new therapies are approved by the FDA, doctors have more options for their patients, leading to better and more patient-centered care. Ideally, a patient who has a concern about their cognition will see their primary care physician, have the confidence to raise the concern, be screened for potential impairment, and if appropriate be referred to a physician with the skill, experience, and infrastructure to consider this patient for a new Alzheimer’s therapy. Key Question: What steps are leading clinicians and health systems taking to ensure that each Alzheimer’s patient who qualifies gets the right drug and in time to make a difference?

View SessionWatch Replay